Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.
European Commission Approves Cilta-Cel for R/R Myeloma After at Least 1 Prior Line of Therapy
Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma
FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies
FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma
FDA’s ODAC Recognizes MRD as an Accepted End Point for Accelerated Approval in Multiple Myeloma
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma